We look forward to this year’s World Vaccine Congress in Washington DC. With the conference in its 25th year, and the event continuing to grow in size, we believe this to be a great place to connect, talk to and meet with new and old colleagues and contemporaries.
Please do visit us at booth 215 and chat with the team present, not only will the team be present at the booth, but our Senior Director of Clinical Science Alex Mann will be presenting in the influenza and respiratory track on April 23rd at 14:40 titled “Raising the Temperature: New Challenge Agents, Febrile Illness, and Vaccine Efficacy Testing”.
As the global leader in human challenge trials, hVIVO has a long and unique history in the field of clinical trials. Having now moved to the new facility in the UK’s life science quarter in London’s Canary Wharf, we have expanded the services we offer with not only a standalone specialist virology and immunology laboratory, with BSL 2 and BSL 3 facilities, hLAB but a dedicated outpatient unit for Phase II and Phase III trials.
At the beginning of 2025 we added to the Group with the acquisition of CRS Early Phase and along with our existing consulting arm, Venn Life Sciences we offer end-to-end services from discovery through drug development and lifecycle management. CRS Early Phase, focuses on Phase I and Phase II studies whilst Venn Life Science’s expertise covers the drug development pathway, with SME’s in CMC, non-clinical, clinical as well as regulatory affairs, biostatistics and study design.
At hVIVO we have been studying Influenza for over 20 years and running human challenge studies with our flu disease models for over 15 years. We have delivered flu challenge studies for industry, governmental and academic partners, making our tool the most well-used commercial flu disease models available on the market. As well as our established influenza A model, we have developed the first Influenza B challenge model, you can find out more about this on our Influenza model page.
We are also in the process of developing a hMPV human challenge model. We recently signed a contract with a new biopharmaceutical company to complete the final stage of the characterisation study, to expand the dataset and further strengthen our model. This is expected to commence in the first half of 2025, on pace for our goal of commencing human challenge trials in the second half of 2025. You can read more about our hMPV challenge model here.
As the global leader in human challenge trials, hVIVO has vast experience investigating RSV infection, having inoculated almost 2000 participants with RSV, hVIVO has the only commercially available RSV challenge model, which has been a part of the accelerated development of a number of vaccines/antivirals in avoiding the risks and pitfalls of expensive large-scale Phase II and Phase III studies.
We also have a Covid-19 challenge model that offers drug and vaccine developers a wide range of solutions to speed up the development of their product. Using human challenge studies allows us to move past the unpredictability of future Covid-19 outbreaks, and quickly and efficiently obtain efficacy data.
Presented by Alex Mann. Senior Director of Clincial Science, hVIVO
Date: April 23rd
Time: 14:40
Track: Influenza & Respiratory
Room: 202A
